MILFORD, Mass.--(BUSINESS WIRE)--Aug. 25, 2004--Waters Corporation (NYSE: WAT) today announced that the Company is shipping to customers its ACQUITY Ultra Performance LC(TM) system. Introduced earlier this year and broadly recognized as a major innovation in liquid chromatography technology, ACQUITY UPLC(TM) received the Editors' Gold Award at this year's Pittsburgh Conference. During the Company's July 27, 2004 second quarter earnings conference call, management noted that ACQUITY UPLC shipments were expected to ramp in August to reflect higher production volumes enabled by additional manufacturing testing and software evaluation. Today's announcement confirms that this shipment plan is on schedule.
The Company plans to provide further details regarding ACQUITY UPLC in its third quarter conference call in October.
About ACQUITY Ultra Performance LC - The Waters ACQUITY UPLC system basic configuration consists of a binary solvent manager, sample manager, ACQUITY UPLC Column chemistry, column heater module and either tunable UV and/or photodiode array detectors. An optional sample organizer is available with a capacity for up to 21 microtitre plates or up to eight vial racks. The system is controlled by Waters Empower(TM) or MassLynx(TM) chromatography/mass spectrometry software. A new graphical console designed for the ACQUITY UPLC System will provide control, status and advanced diagnostic information to the scientist.
For more information on the ACQUITY UPLC System, visit Waters' website at www.waters.com/acquity.
Waters Corporation holds worldwide leading positions in three complementary analytical technologies - high performance liquid chromatography (HPLC), mass spectrometry (MS) and thermal analysis (TA). These markets account for $4.5 - $5.0 billion of the overall $20+ billion analytical instrument market.
This press release contains "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward looking statements. Without limiting the foregoing, the words, "believes", "anticipates", "plans", "expects", "intends", "appears", "estimates", "projects", and similar expressions are intended to identify forward looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements discussed in this release for a variety of reasons, including, without limitation, shipments of new product introductions expected in the upcoming quarters such as ACQUITY UPLC and tandem quadrupole systems, loss of market share through competition, introduction of competing products by other companies, pressures on prices from competitors and/or customers, regulatory obstacles to new product introductions, lack of acceptance of new products, changes in the demands of the Company's healthcare and pharmaceutical company customers, changes in the healthcare market and the pharmaceutical industry, changes in distribution of the Company's products, service and distribution organizations, and foreign exchange fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-K for the year ended December 31, 2003, as filed with the Securities and Exchange Commission, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this press release and should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future.
CONTACT: Waters Corporation
Gene Cassis, 508-482-2349
SOURCE: Waters Corporation